This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment of MODY

Authoring team

treatment

seek expert advice.

GCK - MODY

  • general consensus is that the majority of these patients do not require treatment since insulin or oral hypoglycaemic agents has little effect on glycemia in this group
  • however in pregnancy insulin may be required to prevent excess fetal growth

HNF1A-MODY and HNF4A-MODY

  • low dose sulfonylureas are recommended as first line treatment for patients with HNF1A/HNF4A-MODY, however most patients will progress to insulin treatment with time
  • a short-acting sulfonylurea such as nateglinide may sometimes be used as an alternative

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.